Overview

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1 chronic hepatitis C infection.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin